Properties
What is it?
International Name - piracetam Clinical-Pharmacological Group: Central Nervous System → Cerebral Metabolism Enhancers → Nootropic Preparations Composition 1 ml of the preparation contains: Active substance - piracetam 200 mg Excipients – sodium acetate trihydrate, diluted acetic acid, water for injection. Indications Symptomatic treatment of psychoorganic syndrome, particularly in elderly patients complaining of memory impairment, dizziness, reduced concentration and general activity, mood swings, behavioral disorders, gait disturbances, as well as in patients with Alzheimer's disease and Alzheimer's type senile dementia. Treatment of stroke consequences (chronic stage of ischemic stroke), such as speech disorders, emotional, motor, and mental activity disorders. Chronic alcoholism – treatment of psychoorganic and abstinence syndromes. Comatose states (recovery period), including after head trauma and intoxication. Treatment of vascular genesis dizziness. Treatment of cortical myoclonus, monotherapy and complex therapy. In complex therapy of sickle cell anemia. Dosage and Administration Administered intravenously and intramuscularly. For symptomatic treatment of chronic psychoorganic syndrome, 2-4g is prescribed depending on the severity of symptoms, with a subsequent dose increase to 4-6g per day, for a treatment course of 10-15 days. For treatment of stroke consequences (chronic stage), 4-8 g/day is prescribed. The treatment course is 10-15 days, and if necessary, a repeat course is conducted after 6-8 weeks. For treatment of comatose states and in individuals with perceptual difficulties after head trauma, the initial dose is 9-12 g/day, and the maintenance dose is 2.4 g/day. Treatment lasts at least 3 weeks. For alcoholic abstinence syndrome – 12 g/day. The maintenance dose is 2.4 g/day. For treatment of dizziness and related disorders, 2.4-4.8 g/day, for a treatment course of 10-15 days. For sickle cell anemia, the daily prophylactic dose is 160 mg/kg body weight, divided into four equal doses. During crisis periods – 300 mg/kg intravenously. Contraindications Individual intolerance to piracetam and pyrrolidone derivatives, as well as other components of the preparation. Acute stage of hemorrhagic stroke. End-stage renal failure (creatinine clearance not less than 20 ml/min). Children under 1 year of age. Pregnancy and Lactation The use of the preparation is contraindicated during pregnancy and lactation. Special Instructions Due to piracetam's effect on platelets, it is recommended to prescribe the preparation with caution in patients with hemostasis disorders, during surgical operations, or in patients with severe bleeding symptoms. In patients with cortical myoclonus, abrupt discontinuation of treatment should be avoided, as it may lead to the recurrence of seizures. In case of long-term treatment in elderly patients, regular monitoring of kidney function is recommended, and dose adjustment based on creatinine clearance test results should be performed if necessary. Reaches the membrane of the hemodialysis filtration apparatus.
